Confluence Investment Management LLC raised its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY – Free Report) by 3.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 12,922 shares of the company’s stock after acquiring an additional 459 shares during the period. Confluence Investment Management LLC’s holdings in Roche were worth $448,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. AlphaMark Advisors LLC acquired a new position in Roche in the 1st quarter worth $34,000. Wetzel Investment Advisors Inc. acquired a new position in Roche in the 4th quarter worth $53,000. First Horizon Advisors Inc. boosted its stake in Roche by 19.8% in the 4th quarter. First Horizon Advisors Inc. now owns 2,066 shares of the company’s stock worth $75,000 after purchasing an additional 342 shares during the period. GAMMA Investing LLC acquired a new position in shares of Roche during the 4th quarter worth about $146,000. Finally, Waldron Private Wealth LLC acquired a new position in shares of Roche during the 4th quarter worth about $294,000.
Roche Stock Performance
Shares of OTCMKTS RHHBY traded down $0.01 during trading on Monday, hitting $40.71. 1,483,500 shares of the company traded hands, compared to its average volume of 2,465,619. The business’s fifty day moving average is $35.56 and its 200 day moving average is $33.38. Roche Holding AG has a fifty-two week low of $29.20 and a fifty-two week high of $41.15. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.35 and a quick ratio of 1.04.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on RHHBY
About Roche
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Read More
- Five stocks we like better than Roche
- How to Evaluate a Stock Before Buying
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- How to Invest in Small Cap Stocks
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
- How to Read Stock Charts for Beginners
- Why Warren Buffett Just Sold Half His Stake in Apple Stock
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.